Neumora Therapeutics Inc.
NMRA
Get informed when a big investor buys or sells
+ FollowMarket Cap$135.26M
Close$
$1.11
52.6% upside
Current Fair Value
52.6% upsideUndervalued by 52.6% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $135.26 Million |
|---|---|
| Enterprise Value | $18.76 Million |
| Dividend Yield | $- (-) |
| Earnings per Share | $-1.45 |
| Beta | 2.74 |
| Outstanding Shares | 185,163,000 |
Return
| Return on Equity | -477.87% |
|---|---|
| Return on Assets | -169.86% |
| Return on Invested Capital | -218.44% |
Valuation & Multiples
| P/E Ratio | -0.59 |
|---|---|
| PEG | 3.24 |
| Price to Sales | - |
| Price to Book Ratio | - |
| Enterprise Value to Revenue | - |
| Enterprise Value to EBIT | -0.09 |
| Enterprise Value to Net Income | -1 |
| Total Debt to Enterprise | 0.02 |
| Debt to Equity | 0.01 |
Revenue Sources
No data
Insider Trades
Last Earnings Call
Report Date
August 14, 2026
EPS Estimate
$-0.24
Average shareholder expectationRevenue Estimate
-
Average shareholder expectationNext Earnings Call
Expected Date
November 4, 2026
EPS Estimate
$-0.20
Average shareholder expectationRevenue Estimate
-
Average shareholder expectationInstitutional Put/Call Ratio
Market sentiment based on institutional option activity.
| Put/Call Ratio | 0.2058▼ 40.64% |
|---|---|
| Total Calls | 5,069,600▲ 297.12% |
| Total Puts | 1,043,400▲ 33.51% |
Institutional Ownership
Holdings and activity of institutional investors.
| Ownership % | 41.48%▲ 2.35% |
|---|---|
| Total Invested | $130.61M▼ 4.84% |
| Investors Holding | 123▲ 2.00% |
ESG Score
No data